All posts by CAC2

Assorted News from the Last Week: The simple act of asking young patients about their symptoms regularly during cancer treatment can help them get more supportive care and reduce distressing side effects, according to the results of two new clinical trials. A simple change to the chemotherapy regimen for people with Hodgkin lymphoma could reduce the long-term health impacts that can result from treatment. Indian researchers are working on developing less expensive treatment for children's blood cancers. Frequent copy number gain of MCL1 is a therapeutic target for osteosarcoma. The survival rate for children high risk neuroblastoma could one day [...] Read more

Assorted News from the Last Week: CAC2 Individual Member Jennifer Flowers writes compellingly about "When the National Drug Shortage Becomes Personal" for her. Published in JAMA: "Stakeholder Perspectives on Randomized Clinical Trials for Children With Poor-Prognosis Cancers." Many CAC2 Members contributed to this of how and when randomized clinical trials (RCTs) should be deployed to best meet the needs of all involved. Reported at the ASH meeting this week: An investigational CAR T-cell therapy induced responses in nearly every single patient with childhood B-cell acute lymphoblastic leukemia (B-ALL). Children with newly diagnosed B-cell acute lymphoblastic leukemia (B-ALL) lived significantly longer [...] Read more

Assorted News from the Last Week: Last week the FDA reported that it is investigating reports of blood cancers -- including life-threatening cases of myelodysplastic syndrome and acute myeloid leukemia -- in patients with early, active cerebral adrenoleukodystrophy (CALD) who were treated with elivaldogene autotemcel (eli-cel; Skysona). Cervical cancer deaths have plunged dramatically among women under age 25, and researchers at MUSC Hollings Cancer Center believe this is likely due to HPV vaccination. An international research team including researchers from Augsburg University Medicine has made significant progress in the risk assessment and treatment of extracranial malign rhabdoid tumors. Giselle Saulnier [...] Read more

Assorted News from the Last Week: In conjunction with the European Medicines Agency (EMA), the FDA Oncology Center of Excellence (OCE) held a one-hour Conversations on Cancer public panel discussion to examine an array of challenging decisions faced by members of the pediatric oncology community. The panel discussion featured current CAC2 Board Member Nicole Scobie (Zoe4Life) and past CAC2 Board Member Donna Ludwinski (Solving Kids’ Cancer). Regular symptom screening in patients with pediatric cancer can lead to a reduced symptom burden, according to a pair of studies published in JAMA Pediatrics and JAMA Suicide rates for young male cancer survivors [...] Read more

Assorted News from the Last Week: Electronic symptom screening in kids with cancer boosts quality of care. DIPG Research in Nature: brain tumor yields, in some young people, to CAR-T therapy. Plus a profile on Dr. Michelle Manje's approach to DIPG research (gated) Member blog post by Student Member Joshua Omale: "Reflections from International Cancer Week 2024" The NCCR Data Platform is the nation’s first data-sharing resource to link childhood, adolescent, and young adult records across population-based cancer registries and real-world data partners. The Data Platform links social drivers of health, pharmacy claims, and medical claims data, as well as [...] Read more

Assorted News from the Last Week: Navigating gatekeeping challenges in pediatric and young adult palliative oncology and end-of-life research. Active participation by patients and families in studies helps identify more effective therapies that improve quality of life and survival. My daughter's diagnosis of a rare and aggressive brain tumor at 3 years old made me strongly consider whether or not to have her treated with radiation. Genetic and epigenetic bases of long-term adverse effects of childhood cancer therapy. Korean patients still waiting for access and insurance approval for Qarziba (dinutuximab beta), which was approved as therapy for treating high-risk and [...] Read more